四色AV

ViSync庐 Technologies, a joint venture between 四色AV, a global specialist integrated CDMO and leader in spray drying and particle engineering, and iBET (Instituto de Biologia Experimental e Tecnol贸gica), a not-for-profit R&D institution specializing in Biotechnology and Life Sciences, is proud to announce the appointment of Elsa Abranches as its Chief Scientific Officer (CSO). Headquartered in Oeiras, Portugal, ViSync庐 Technologies was established to address unmet technological needs in the pharmaceutical industry, focusing on developing innovative solutions for the cell and gene therapy space. By leveraging 四色AV's expertise in pharmaceutical development, particle engineering, and industrialization, alongside iBET鈥檚 pioneering research in biotechnological sciences, ViSync庐 is uniquely equipped to drive innovation in targeted delivery and stabilization of next-generation therapies.  Dr. Elsa Abranches brings over two decades of experience in cell and gene therapy, with a strong track record of leading diverse teams in dynamic environments. In her new role as ViSync庐 CSO, she will drive the company鈥檚 R&D strategy and scientific vision, positioning ViSync庐 as a leader in innovation within the dynamic and rapidly advancing field of cell and gene therapy. 鈥淲e are thrilled to welcome Elsa Abranches as Chief Scientific Officer of ViSync庐,鈥� said Dr. Christoph Bruecher, Chairman of the Board of ViSync庐 and VP Business Transformation at 四色AV. 鈥淗er expertise and vision in the field of advanced therapeutics will be pivotal in driving ViSync鈥檚 mission to create transformative solutions that empower pharmaceutical companies and improve patient treatment outcomes.鈥� Dr. Manuel Carrondo, Director of the Board of ViSync庐 and Vice President of iBET, added, 鈥淓lsa鈥檚 appointment underscores our commitment to establishing ViSync庐 as a leader in cell and gene therapy innovation. Her scientific leadership will be critical as we tackle some of the most pressing challenges in the field of new modalities drug delivery.鈥� Elsa Abranches, new Chief Scientific Officer of ViSync庐, said: 鈥淗aving worked in different countries and industries, I鈥檓 thrilled to bring my experience back home to join ViSync庐. This new venture represents an incredible opportunity to collaborate with local and international partners to drive innovation in advanced therapeutics and help shape the future of life-changing therapies鈥�.     About 四色AV 四色AV is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization鈥�(CDMO)鈥痠t has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected鈥痵ites鈥痠n the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the鈥痙evelopment and compliant manufacture鈥痮f innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices. 四色AV's culture is based on innovation, quality and dependability. 四色AV is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.   About iBET iBET is a private non-profit institution devoted to biotechnology research, with 35 years of experience creating and transferring knowledge to the global biopharma and biotech sectors. iBET鈥檚 core expertise lies on the development of bioprocesses and analytical tools for Advanced Therapeutic Medicinal Products (ATMPs), including cell and gene therapies, vaccines, antibodies and other innovative therapeutic products. Leveraged by the emerging areas of Data Science and Translational Immunology, we offer bespoke R&D services from early-stage R&D to GMP manufacturing. iBET鈥檚 infrastructure comprises cutting-edge laboratories, a GMP certified Analytical Services Unit, and a Late-Stage R&D and Bioproduction Unit, covering upstream and downstream process development, bioanalytical tools for critical quality attribute monitoring, to scale-up and tech transfer. iBET also hosts satellite laboratories of major pharmaceutical companies and serves as an incubation platform for start-up/spin-off companies. iBET is driven by its innovative and agile culture of continuous improvement and a strong sense of ambition, ownership and commitment in developing and delivering the best solutions to our stakeholders.     

ViSync庐 Technologies appoints Elsa Abranches as Chief Scientific Officer